Heron Therapeutics stock gained 15.86 percent to USD 0.38
Published on 10/08/2026 at 07:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Heron Therapeutics (ISIN US4277461020) stock gained 15.86 percent from a USD 0.33 prior close to USD 0.38 on Nasdaq on October 7, 2026, at 4:00 p.m. ET. The move came with 3,668,095 shares traded, while the stock remained below its 52-week high of USD 1.58.
Trading volume rises with the price
The session range was USD 0.33 to USD 0.39, placing the last price near the upper end of that day. Heron Therapeutics had a market capitalization of USD 72.7 million on October 7, 2026, against a 52-week range of USD 0.26 to USD 1.58.
The 15.86 percent daily gain is the clearest short-term signal in the current quotation. It also leaves the stock 75.9 percent below the 52-week high, keeping the market value sensitive to changes in product sales and financing conditions.
Q2 revenue reached USD 37.7 million
According to Yahoo Finance on August 10, 2026, Heron reported Q2 2026 net revenue of USD 37.7 million, up from USD 34.7 million in Q1 2026 and USD 37.2 million in the comparable quarter. Gross margin was 69.3 percent, while net loss widened to USD 5.5 million from USD 2.4 million a year earlier.
The product mix explains why the revenue comparison is more important than the headline loss. ZYNRELEF revenue reached USD 11.1 million, up 35 percent year over year, while APONVIE revenue rose 74 percent year over year to USD 4.2 million, according to Yahoo Finance.
License deal adds a future product route
Heron entered a multi-product development and license agreement with Long Grove Pharmaceuticals effective September 23, 2026. As StockTitan reports from the 8-K, the agreement gives Heron an exclusive sublicensable U.S. license for certain products and a non-exclusive worldwide manufacturing license for U.S. sales.
The initial term lasts 10 years after the first commercial sale, with automatic two-year renewals. The arrangement also requires regulatory milestone payments, sales-based milestone payments and royalties, so its commercial value depends on future development and product uptake rather than an immediate revenue contribution.
November 3 is the next checkpoint
According to MarketBeat, Heron is scheduled to report Q3 2026 results on November 3, 2026, before the market opens, with the conference call listed for 8:30 a.m. ET. That report should give investors a fresh view of sales, cash use and the commercial effect of the revised product strategy.
Heron Therapeutics stock was last at USD 0.38
Heron Therapeutics stock was last at USD 0.38 on Nasdaq on October 7, 2026, at 4:00 p.m. ET, after a 15.86 percent session gain. The next earnings report on November 3, 2026, is the next dated operating checkpoint.
Key facts on Heron Therapeutics stock
- Company: Heron Therapeutics, Inc.
- ISIN: US4277461020
- Ticker: HRTX
- Trading venue: Nasdaq Capital Market
- Price (as of October 7, 2026, 4:00 p.m. ET): USD 0.38
- Market capitalization: USD 72.7 million (as of October 7, 2026)
- 52-week range: USD 0.26-1.58 (as of October 7, 2026)
- Sector / Industry: Health Care / Biotechnology
Upcoming dates for Heron Therapeutics stock
- November 3, 2026: Q3 2026 results and conference call
